NCT00842634View on ClinicalTrials.gov

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
HIVHIV Infections
Interventions
BIOLOGICAL

ZFN modified T cells

A single infusion of 5-10 billion ZFN Modified CD4+ T Cells

OTHER

Structured Treatment Interruption

Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)

Trial Locations (2)

10461

Jacobi Medical Cener, The Bronx

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Sangamo Therapeutics
All Listed Sponsors
collaborator

Sangamo Therapeutics

INDUSTRY

lead

University of Pennsylvania

OTHER